Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
MYL's Cash to Debt is ranked lower than
98% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. MYL: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s 10-Year Cash to Debt Range
Min: 0.02  Med: 1.83 Max: 44.56
Current: 0.03
0.02
44.56
Equity to Asset 0.41
MYL's Equity to Asset is ranked lower than
79% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MYL: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s 10-Year Equity to Asset Range
Min: 0.19  Med: 0.76 Max: 0.92
Current: 0.41
0.19
0.92
Interest Coverage 4.06
MYL's Interest Coverage is ranked lower than
90% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2065.49 vs. MYL: 4.06 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s 10-Year Interest Coverage Range
Min: 0.83  Med: 3.59 Max: 9.19
Current: 4.06
0.83
9.19
F-Score: 6
Z-Score: 2.37
M-Score: -2.17
WACC vs ROIC
8.64%
9.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.16
MYL's Operating margin (%) is ranked higher than
74% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. MYL: 16.16 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s 10-Year Operating margin (%) Range
Min: 2.31  Med: 18.41 Max: 36
Current: 16.16
2.31
36
Net-margin (%) 11.05
MYL's Net-margin (%) is ranked higher than
68% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. MYL: 11.05 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s 10-Year Net-margin (%) Range
Min: -3.53  Med: 14.33 Max: 26.04
Current: 11.05
-3.53
26.04
ROE (%) 19.57
MYL's ROE (%) is ranked higher than
81% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. MYL: 19.57 )
Ranked among companies with meaningful ROE (%) only.
MYL' s 10-Year ROE (%) Range
Min: -14.72  Med: 14.19 Max: 29.99
Current: 19.57
-14.72
29.99
ROA (%) 5.17
MYL's ROA (%) is ranked higher than
58% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYL: 5.17 )
Ranked among companies with meaningful ROA (%) only.
MYL' s 10-Year ROA (%) Range
Min: -2.47  Med: 7.85 Max: 18.43
Current: 5.17
-2.47
18.43
ROC (Joel Greenblatt) (%) 24.36
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. MYL: 24.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.11  Med: 37.59 Max: 92.62
Current: 24.36
4.11
92.62
Revenue Growth (3Y)(%) 11.60
MYL's Revenue Growth (3Y)(%) is ranked higher than
62% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MYL: 11.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.1  Med: 15.55 Max: 54.5
Current: 11.6
-6.1
54.5
EBITDA Growth (3Y)(%) 11.30
MYL's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. MYL: 11.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20  Med: 11.85 Max: 107
Current: 11.3
-20
107
EPS Growth (3Y)(%) 24.20
MYL's EPS Growth (3Y)(%) is ranked higher than
77% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MYL: 24.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.8  Med: 11.80 Max: 110.4
Current: 24.2
-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MYL Guru Trades in Q2 2014

Pioneer Investments 226,453 sh (New)
First Eagle Investment 1,241,991 sh (+83.88%)
Mario Gabelli 13,800 sh (+6.15%)
John Hussman 50,000 sh (unchged)
John Paulson 12,130,700 sh (unchged)
Steven Cohen 83,700 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Andreas Halvorsen Sold Out
Louis Moore Bacon 100,000 sh (-25.46%)
Scott Black 201,925 sh (-26.46%)
Jim Simons 652,200 sh (-53.46%)
Paul Tudor Jones 4,200 sh (-99.03%)
» More
Q3 2014

MYL Guru Trades in Q3 2014

Ray Dalio 57,106 sh (New)
Paul Tudor Jones 20,015 sh (+376.55%)
Louis Moore Bacon 435,000 sh (+335.00%)
Vanguard Health Care Fund 15,444,880 sh (+223.41%)
John Paulson 12,494,700 sh (+3.00%)
Pioneer Investments 282,805 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Steven Cohen Sold Out
Scott Black 199,406 sh (-1.25%)
Mario Gabelli 10,000 sh (-27.54%)
Jim Simons 465,200 sh (-28.67%)
First Eagle Investment 809,603 sh (-34.81%)
» More
Q4 2014

MYL Guru Trades in Q4 2014

Joel Greenblatt 673,287 sh (New)
Paul Tudor Jones 254,152 sh (+1169.81%)
Pioneer Investments 691,198 sh (+144.41%)
John Paulson 14,948,400 sh (+19.64%)
First Eagle Investment 841,779 sh (+3.97%)
Louis Moore Bacon 200,000 sh (unchged)
Mario Gabelli 10,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Jim Simons Sold Out
Vanguard Health Care Fund 15,037,080 sh (-2.64%)
Ray Dalio 52,706 sh (-7.70%)
Scott Black 181,796 sh (-8.83%)
Louis Moore Bacon 36,196 sh (-91.68%)
» More
Q1 2015

MYL Guru Trades in Q1 2015

Steven Cohen 253,300 sh (New)
Tom Russo 5,850 sh (New)
Pioneer Investments 826,251 sh (+19.54%)
Vanguard Health Care Fund 15,891,898 sh (+5.68%)
Scott Black 187,570 sh (+3.18%)
Mario Gabelli 10,000 sh (unchged)
Paul Tudor Jones 125,000 sh (unchged)
John Paulson 14,948,400 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
First Eagle Investment 586,016 sh (-30.38%)
Paul Tudor Jones 109,447 sh (-56.94%)
Joel Greenblatt 16,021 sh (-97.62%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Mylan NV

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Tom Russo Buys 3 New Stocks in Q1
Tom Russo (Trades, Portfolio) added three new stocks to his portfolio during Q1, including an insurance and pharmaceutical company, according to GuruFocus Real Time Picks. Read more...
Vanguard Health Care Fund Comments on Mylan NV
We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.53
MYL's P/E(ttm) is ranked higher than
58% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.90 vs. MYL: 25.53 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s 10-Year P/E(ttm) Range
Min: 7.05  Med: 23.39 Max: 112.56
Current: 25.53
7.05
112.56
Forward P/E 14.03
MYL's Forward P/E is ranked higher than
83% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. MYL: 14.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.20
MYL's PE(NRI) is ranked higher than
58% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.00 vs. MYL: 30.20 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s 10-Year PE(NRI) Range
Min: 7.05  Med: 23.60 Max: 200.11
Current: 30.2
7.05
200.11
P/B 3.01
MYL's P/B is ranked higher than
50% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. MYL: 3.01 )
Ranked among companies with meaningful P/B only.
MYL' s 10-Year P/B Range
Min: 0.64  Med: 2.67 Max: 7.02
Current: 3.01
0.64
7.02
P/S 2.89
MYL's P/S is ranked higher than
50% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. MYL: 2.89 )
Ranked among companies with meaningful P/S only.
MYL' s 10-Year P/S Range
Min: 0.41  Med: 1.83 Max: 4.61
Current: 2.89
0.41
4.61
PFCF 84.41
MYL's PFCF is ranked lower than
73% of the 275 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.38 vs. MYL: 84.41 )
Ranked among companies with meaningful PFCF only.
MYL' s 10-Year PFCF Range
Min: 8.81  Med: 19.65 Max: 115.24
Current: 84.41
8.81
115.24
POCF 22.49
MYL's POCF is ranked higher than
55% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. MYL: 22.49 )
Ranked among companies with meaningful POCF only.
MYL' s 10-Year POCF Range
Min: 6.09  Med: 12.67 Max: 40.56
Current: 22.49
6.09
40.56
EV-to-EBIT 29.32
MYL's EV-to-EBIT is ranked lower than
60% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. MYL: 29.32 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s 10-Year EV-to-EBIT Range
Min: -10.7  Med: 16.40 Max: 33
Current: 29.32
-10.7
33
PEG 3.64
MYL's PEG is ranked lower than
57% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.94 vs. MYL: 3.64 )
Ranked among companies with meaningful PEG only.
MYL' s 10-Year PEG Range
Min: 0.45  Med: 2.41 Max: 11.64
Current: 3.64
0.45
11.64
Shiller P/E 42.70
MYL's Shiller P/E is ranked lower than
61% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.83 vs. MYL: 42.70 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s 10-Year Shiller P/E Range
Min: 10.98  Med: 25.09 Max: 1402
Current: 42.7
10.98
1402
Current Ratio 1.40
MYL's Current Ratio is ranked lower than
74% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MYL: 1.40 )
Ranked among companies with meaningful Current Ratio only.
MYL' s 10-Year Current Ratio Range
Min: 1.28  Med: 3.44 Max: 8.52
Current: 1.4
1.28
8.52
Quick Ratio 1.04
MYL's Quick Ratio is ranked lower than
73% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MYL: 1.04 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s 10-Year Quick Ratio Range
Min: 0.85  Med: 2.85 Max: 6.76
Current: 1.04
0.85
6.76
Days Inventory 150.90
MYL's Days Inventory is ranked lower than
67% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. MYL: 150.90 )
Ranked among companies with meaningful Days Inventory only.
MYL' s 10-Year Days Inventory Range
Min: 88.95  Med: 147.08 Max: 175.9
Current: 150.9
88.95
175.9
Days Sales Outstanding 104.95
MYL's Days Sales Outstanding is ranked lower than
72% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. MYL: 104.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s 10-Year Days Sales Outstanding Range
Min: 49.61  Med: 83.48 Max: 107.26
Current: 104.95
49.61
107.26

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.89
MYL's Price/Projected FCF is ranked higher than
61% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. MYL: 1.89 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s 10-Year Price/Projected FCF Range
Min: 0.62  Med: 1.39 Max: 2.53
Current: 1.89
0.62
2.53
Price/DCF (Earnings Based) 3.86
MYL's Price/DCF (Earnings Based) is ranked lower than
80% of the 56 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MYL: 3.86 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.60
MYL's Price/Median PS Value is ranked lower than
71% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. MYL: 1.60 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 1.94 Max: 3.77
Current: 1.6
0.36
3.77
Price/Peter Lynch Fair Value 2.60
MYL's Price/Peter Lynch Fair Value is ranked lower than
68% of the 148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. MYL: 2.60 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67  Med: 1.55 Max: 10.2
Current: 2.6
0.67
10.2
Earnings Yield (Greenblatt) (%) 3.42
MYL's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. MYL: 3.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3  Med: 5.70 Max: 15.1
Current: 3.42
3
15.1
Forward Rate of Return (Yacktman) (%) 12.02
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
62% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. MYL: 12.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 3.6  Med: 6.30 Max: 39.2
Current: 12.02
3.6
39.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:0R5P.UK, MYL1.Switzerland, 6MY.Germany,
Mylan NV was incorporated in Pennsylvania in 1970. The Company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline. Additionally, the Company has a specialty business that is engaged in the respiratory and allergy therapies. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while engaging on those products that are difficult to formulate and manufacture, and typically have longer life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, it offers antiretroviral therapies upon which HIV/AIDS patients in developing countries depend. The Company operates in two segments, Generics and Specialty. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages in the development, manufacture and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
Tom Russo Buys 3 New Stocks in Q1 May 18 2015 
Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
Teva Eyeing Mylan For $40 Billion Apr 23 2015 
CalAmp and Illumina Significant Earnings Growth; Perrigo Rebuffs Takeover Offer Apr 22 2015 
Vanguard Health Care Fund Comments on Mylan NV Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 

More From Other Websites
Business Highlights Jul 28 2015
Mylan selloff draws bullish trades Jul 28 2015
There's 'Life After Teva' For Mylan, Says Leerink Jul 28 2015
BMO Ups Teva To Buy; Allergan Deal 'Solidifies Leadership' In Generics Jul 28 2015
Has Mylan Labs Been Stichting it to Shareholders? A Lawsuit Says 'Yes!' Jul 28 2015
Faber Report: Mylan continues fight for Perrigo Jul 28 2015
10 S&P 500 stocks with the biggest declines over the past week Jul 28 2015
Hikma to buy Boehringer's U.S. generic drug business for $2.65 billion Jul 28 2015
Hikma to buy Boehringer's U.S. generic drug business for $2.65 bln Jul 28 2015
PRESS DIGEST- Wall Street Journal - July 28 Jul 27 2015
PRESS DIGEST- New York Times business news - July 28 Jul 27 2015
Teva’s Allergan Deal Looks a Healthier Mouthful Jul 27 2015
Mylan’s Leverage to Resist Teva Deal Reveals Shift in Rules Jul 27 2015
Mylan independence from Teva's embrace comes with a price Jul 27 2015
Mylan independence from Teva's embrace comes with a price Jul 27 2015
[video]Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid Jul 27 2015
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid Jul 27 2015
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid Jul 27 2015
Teva to buy Allergan generic business for $40.5 bln, drops Mylan bid Jul 27 2015
Next biotech deal brewing? Jul 27 2015
Teva Tags Allergan's Generics: $40.5 Bil Jul 27 2015
Mylan Shares Tank After Teva Pharmaceutical Nixes Takeover Bid Jul 27 2015
U.S. stocks follow China’s rout with 5th straight decline Jul 27 2015
Mylan to gather shareholders Aug. 28 in Amsterdam to decide Perrigo bid Jul 27 2015
Analysts expect more tie-ups in generic drug business Jul 27 2015
Analysts expect more tie-ups in generic drug business Jul 27 2015
Trending Now: MYL Jul 27 2015
Teva stock surges on Allergan deal Jul 27 2015
Teva Snaps Up Allergan's Generics Arm, Dumping Mylan Jul 27 2015
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid Jul 27 2015
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid Jul 27 2015
Israel's Teva buys Allergan generic drug company for $40.5B Jul 27 2015
Teva to buy Allergan generic drug unit for $40.5 bn Jul 27 2015
Teva Withdraws Proposal to Acquire Mylan Jul 27 2015
Botox owner Allergan sells generic drugs unit to Teva for $41bn Jul 27 2015
Botox owner Allergan in talks to sell generic drugs unit to Teva for $45bn Jul 27 2015
Teva to buy Allergan generic drug unit for $40.5 bn Jul 26 2015
Teva nears deal for Allergan's generic drugs unit - source Jul 25 2015
Mylan puts up barrier to Teva with Dutch legal maneuver Jul 23 2015
Mylan foundation to block Israel's Teva hostile takeover bid Jul 23 2015
Mylan foundation to block Israel's Teva hostile takeover bid Jul 23 2015
Teva to lift bid for Mylan: report Jul 06 2015
Teva to lift bid for Mylan: report Jul 06 2015
Teva takes 4.6 percent stake in Mylan as part of bid Jun 19 2015
Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V. Jun 19 2015
Big shareholder backs drugmaker Mylan's growth strategy Jun 16 2015
Deals of the day- Mergers and acquisitions Jun 16 2015
Mylan to Present at the Bank of America Merrill Lynch Health Care Conference Jun 08 2015
Mylan Launches Generic INTUNIV® Tablets Jun 08 2015
Mylan is Expanding its Voluntary Nationwide Recall of Select Lots of Injectable Products Due to the... Jun 08 2015
Mylan to Present at the Bernstein Strategic Decisions Conference Jun 08 2015
Mylan to Present at the UBS Global Healthcare Conference Jun 08 2015
Mylan Launches Generic Version of Seasonique® Tablets Jun 08 2015
Mylan to Present at Goldman Sachs 36th Annual Global Healthcare Conference Jun 08 2015
Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy Seretide® Evohaler®... Jun 08 2015
Mylan/Perrigo Clarification Jun 08 2015
Teva accuses Mylan of 'desperate attempt' to suppress bid Jun 08 2015
Exclusive - Teva poised to raise its stake in Mylan -sources Jun 02 2015
Exclusive - Teva poised to raise its stake in Mylan -sources Jun 02 2015
Exclusive - Teva poised to raise its stake in Mylan: sources Jun 02 2015
Teva increases pressure on $40bn takeover target Mylan May 27 2015
Endo pushes further into generics with $8 billion Par Pharma buy May 18 2015
Endo pushes further into generics with $8 bln Par Pharma buy May 18 2015
Perrigo expands Mexican business in $34M deal with Pantheon May 12 2015
Exclusive: Mylan chairman tells investors he would consider buying Teva May 08 2015
Mylan posts 1Q profit May 05 2015
Mylan Confirms First-to-File Patent Challenge Relating to Minivelle® May 05 2015
Teva Provides Additional Detail on Proposed Acquisition of Mylan May 05 2015
Mylan Launches Gilead Sciences' Sovaldi® Tablets in India May 04 2015
Big pharma deals: Mylan raises bid for Perrigo to $35.6 bn Apr 30 2015
Perrigo rejects raised Mylan bid; Teva recommits to Mylan buy Apr 29 2015
Perrigo rejects raised Mylan bid; Teva recommits to Mylan buy Apr 29 2015
Teva Sends Letter to Mylan Board Apr 29 2015
Big pharma deals: Mylan raises bid for Perrigo to $35.6 bn Apr 29 2015
Offer Update Apr 29 2015
Perrigo Rejects Latest Mylan Unsolicited Offer Apr 29 2015
Pharma company Mylan raises bid for Perrigo to $35.6 bn Apr 29 2015
Mylan rebuffs Teva again; calls bid low, insincere Apr 27 2015
Big pharma mergers: Mylan boosts offer for Perrigo Apr 24 2015
Generic drugmaker Mylan goes hostile in bid for Perrigo Apr 24 2015
Offer Rejection Apr 24 2015
Mylan says to commence offer for Perrigo Apr 24 2015
Mylan plans to make new offer for Perrigo - CNBC Apr 22 2015
Statement re Unsolicited Proposal From Mylan Apr 22 2015
Generic drugmaker Teva makes $40 billion offer for rival Mylan Apr 21 2015
Top Mylan shareholders seek deal with Teva - sources Apr 21 2015
Exclusive - Perrigo expected to reject Mylan offer as soon as this week: source Apr 21 2015
Mylan plans $5-bn investment in Andhra Pradesh Apr 20 2015
Mylan plans $5 bn investment in Andhra Pradesh Apr 20 2015
Mylan settles Viagra patent litigation with Pfizer Apr 13 2015
Generic drugmaker Mylan offers $29 billion for Perrigo Apr 08 2015
Corrected - UK says Mylan recalls batches of Polish-made antibiotic Jun 19 2014
UK says Mylan recalls batches of Indian-made antibiotic Jun 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK